NCT01534884View on ClinicalTrials.gov

Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

February 28, 2014

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

rituximab

1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.

Trial Locations (1)

Unknown

Hanyang University Medical Center, Seoul

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT01534884 - Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter